China
Blackstone's Ed Huang switches to Asia private wealth role
Ed Huang, who has spent the last two-and-a-half years as COO of The Blackstone Group’s Asia private equity business, will become the firm’s head of private wealth solutions for the region.
China's Didi gets backing from state-owned carmaker
China ride-hailing platform Didi, which delisted from the New York Stock Exchange last year following a scandal-hit post-IPO period, has raised USD 149m in funding from state-backed carmaker GAC Group.
Shangqi hits $575m second close on renminbi fund
Shangqi Capital, a private equity affiliate of Chinese automotive manufacturer SAIC Motor, has completed a second close of CNY 4.2bn (USD 575m) on its latest renminbi-denominated fund, bettering the overall target of CNY 4bn.
State-linked investors back Series D for China's DataCanvas
DataCanvas, a China-based artificial intelligence-driven (AI) big data solutions provider, has raised CNY 300m (USD 41m) in a first tranche of Series D funding with strong support from investors with ties to national-level state-owned enterprises (SOEs).
Trustar, Bain, BPEA EQT target Tyson Foods' China poultry business
US-based meat and processed food maker Tyson Foods has received preliminary bids from private equity firms including Trustar Capital, Bain Capital and BPEA EQT for its China poultry business, according to two sources familiar with the matter.
China's Leadrive raises $81m Series D
Legend Capital and Oriza FoFs have led a CNY 600m (USD 81m) Series D round for Leadrive, a Shanghai-headquartered manufacturer of semiconductor power modules and motor control units used in electric vehicles (EVs).
China-US consumer brand accelerator raises $58m
SuperOrdinary, a global consumer brands accelerator that operates out of Shanghai, New York, and Los Angeles, has raised USD 58m in Series B funding at a valuation of more than USD 800m.
China VC: Amicable divorces
Regulatory pressures are encouraging Chinese VC firms to end longstanding US affiliations, but the impact of impending legislation – even sight unseen – cuts deeper into investor sentiment on China
Temasek's True Light Capital raises $3.3b China fund
True Light Capital, a Singapore-based asset manager established by Temasek Holdings, has raised USD 3.3bn for a fund that invests in companies that have a nexus to or a major business relationship with Greater China.
L Catterton backs beauty industry biotech supplier
L Catterton has led a CNY 200m (USD 27m) Series B round for Trautec, a China-based biotech start-up that develops synthetic proteins used in beauty and healthcare products.
DCM adds partners in Japan, China
DCM has promoted two Asia-based investment professionals – Kenichiro Hara and Fiona Huang, who focus on Japan and China, respectively – to partner.
China healthcare AI start-up Huimei gets $41m Series D
Eastern Bell Capital has led a Series D round of more than CNY 300m (USD 41m) for Huimei Cloud Technology, a China-based provider of artificial intelligence-enabled (AI) software that helps doctors make clinical decisions.
China GP Tiantu Capital targets $253m Hong Kong IPO
Chinese consumer-focused venture capital firm Tiantu Capital has launched a Hong Kong IPO with a view to raising as much as HKD 1.9bn (USD 253m).
PAG to buy cinema business from Chinese property developer
PAG has agreed to acquire Shanghai Xingyi Cinema Management from Hong Kong-listed property developer Seazen for about CNY 1.4bn (USD 187m).
Alibaba confirms Hong Kong IPO plan for logistics unit
Alibaba Group’s logistics unit has filed for an IPO in Hong Kong, potentially creating liquidity events for private equity backers such as Yunfeng Capital, Primavera Capital Group, and Princeville Global, as well as for GIC, Temasek Holdings, and Khazanah...
Matrix, HongShan back China's Qihan Biotech
Matrix Partners China and HongShan (formerly Sequioa Capital China) have joined a USD 16m pre-Series B round for Qihan Biotech, a genome editing player active in human and agricultural therapies.
China's Lynk Pharmaceutical increases Series C to $44m
China-based drug developer Lynk Pharmaceuticals has closed a second tranche of Series C funding, taking the overall size of the round to CNY 322m (USD 44m).
GGV to spin off Asia operation
GGV Capital’s Asia business will sever ties with the firm’s international operation – switching to separate partnerships and a distinct brand – as venture capital continues to feel the impact of the US and China’s conflicting technology agendas.
PE-backed Concord Healthcare pursues HK IPO
Concord Healthcare Group, an onshore subsidiary of US-listed Chinese healthcare business Concord Medical, has filed for an IPO in Hong Kong.
China's Canton Biologics raises $41m Series C
Chinese pharmaceutical industry services provider Canton Biologics has completed a CNY 300m (USD 41m) Series C round led by state-owned SDIC Venture Capital.